Biogen Inc.

Biogen discovers, develops, manufactures, and delivers therapies for neurological and neurodegenerative diseases. Products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis. They also offer ADUHELM for Alzheimers disease, FUMADERM for plaque psoriasis, and RITUXAN for non-Hodgkins lymphoma. The company is developing products for MS, Alzheimers disease, and dementia. Biogen has collaboration agreements with various companies. Founded in 1978, the company is headquartered in Cambridge, Massachusetts.

Overview

Sector

Pharmaceutical

Target Price

324.0 USD

Current Price

125.0 USD

Potential

159%

Strengths

With an appreciation Potential of 156.86%, based on our fundamental analysis, it suggests the stock may be undervalued.
Current Price to Earnings Ratio (11.49) is lower than the sector mean (81.73).
Price to book ratio (1.12) is lower than the sector mean (8.32).
EV/EBITDA (7.51) is lower than the sector mean (21.51).
EV/EBIT (10.51) is lower than the sector mean.
Price to free cash flow (7.45) is lower than the sector mean.
Strong EBITDA Margin of 33.45%.

Weaknesses

The company have lower returns than the sector in which it operates. ROIC (12.50%) is significantly lower than the sector mean (16.32%).

Key Financial Data

Indicator	Value
PER	11.2
EV/EBITDA	7.3
Price/Free Cash Flow'	7.2
ROIC	12.5%
Net Debt/EBITDA	1.3